Connor Clark & Lunn Investment Management Ltd. lessened its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) by 37.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,473 shares of the company’s stock after selling 8,534 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Mirum Pharmaceuticals were worth $282,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of the company. Frazier Life Sciences Management L.P. acquired a new position in shares of Mirum Pharmaceuticals during the 1st quarter worth about $78,543,000. Polar Capital Holdings Plc acquired a new position in shares of Mirum Pharmaceuticals during the 1st quarter worth about $21,441,000. Cadian Capital Management LP acquired a new position in shares of Mirum Pharmaceuticals during the 1st quarter worth about $16,405,000. First Light Asset Management LLC purchased a new stake in shares of Mirum Pharmaceuticals in the 1st quarter valued at about $4,735,000. Finally, Rock Springs Capital Management LP lifted its holdings in shares of Mirum Pharmaceuticals by 8.3% in the 1st quarter. Rock Springs Capital Management LP now owns 1,666,208 shares of the company’s stock valued at $36,690,000 after purchasing an additional 127,394 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.
Mirum Pharmaceuticals Stock Down 0.7 %
MIRM opened at $19.91 on Friday. The business has a 50 day moving average price of $21.79 and a two-hundred day moving average price of $22.92. The company has a market cap of $731.49 million, a PE ratio of -17.78 and a beta of 1.44. Mirum Pharmaceuticals, Inc. has a 52 week low of $12.82 and a 52 week high of $30.55.
Analyst Ratings Changes
Mirum Pharmaceuticals Profile
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
- Get a free copy of the StockNews.com research report on Mirum Pharmaceuticals (MIRM)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.